x

Cardio.Tox Troponin I Service

Cardiotoxicity is a major cause of drug attrition in preclinical and clinical drug development. Drug-induced cardiotoxicity can be functional or structural in nature, and can be developed in a short-term or long-term manner. Investigation of both structural as well as functional toxicity ensures a better prediction of induced cardiotoxic risks.

Structural cardiotoxicity can be determined by detection of the secreted cardiac specific marker Troponin I, which is released into circulation after cardiomyocyte damage induced by myocardial infarct or after treatment with cardiotoxic drugs. The Cardio.Tox Troponin I Service offers an early structural cardiotoxicity assay based on fully validated and functional human iPSC-derived cardiomyocytes and is suitable for high-throughput safety and toxicity screening of compounds.

For a more comprehensive assessment of predicting cardiotoxicity, this assay can be multiplexed with any functional readout including microeletrode array (MEA), impedance or calcium transient assays.

Workflow

Service specifications

Cell type

Human iPSC-derived cardiomyocytes

Service type

Structural toxicity based on biomarker detection

Format

96 wells (Up to 384 wells possible)

Time points

16, 24, 40, 48 and 64 hours after compound addition

Compound concentration*

0.1, 1, 10 µM in medium + 0.1% DMSO

Positive control

Ponatinib

Vehicle control

0.1% DMSO

Parameters

Released Troponin I detection

Timelines

3 Weeks for up to 9 compounds (in triplicates)

Deliverable

A study protocol will be agreed before study initiation. Results will be presented in a study report.

* Suggested concentrations, to be agreed with client